Editor’s Note: Last week the Janssen Pharmaceutical Companies of Johnson & Johnson, expanded its collaboration with the International Partnership for Microbicides (IPM) granting IPM exclusive worldwide rights to develop, manufacture, and market sexual and reproductive health products containing Janssen’s antiretroviral drug dapivirine. This is the latest innovative public-private partnership from the newly established Janssen Global Public Health group and a significant contribution to Johnson & Johnson’s wider efforts to improve public health – and the health of women and girls – worldwide.
Though we’ve made great strides in developing new medicines for HIV, treatment alone is not the solution. Women and girls, particularly in sub-Saharan Africa where the HIV epidemic has hit hardest, are particularly vulnerable to infection. In fact, HIV prevalence among young women in sub-Saharan Africa is more than twice as high as that of young men throughout the region. These women and girls need new prevention tools to empower themselves to protect their health.
Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Janssen, co-authored an Op-Ed appearing on Global Post with Zeda Rosenberg, Chief Executive Officer, IPM discussing this significant effort and the importance of these types of public-private partnerships benefitting women and girls. To read more, visit here.